[
    {
        "outcome_uid": "dee366b9",
        "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their first TNF Inhibitor who are not at target",
        "intervention": "Switch to a 2nd TNF Inhibitor",
        "comparator": "Continue same management",
        "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 20)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "ca0be03a"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to a 2nd TNFi": "8/13 (61.5%)",
                    "Continue 1st TNFi": "4/14 (28.6%)"
                },
                "Annotation": {
                    "data": "1. Switch to IFX.\n2. Continue ETN.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 2.15 (0.85 to 5.48)",
                    "Absolute Effect (95% CI)": "329 more per 1,000 (from 43 fewer to 1,000 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "b2f660d4",
        "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their first TNF Inhibitor who are not at target",
        "intervention": "Switch to a 2nd TNF Inhibitor",
        "comparator": "Continue same management",
        "outcome": "Disease activity (follow up: 4 months; assessed with: ACR 50)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "ca0be03a"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to a 2nd TNFi": "4/13 (30.8%)",
                    "Continue 1st TNFi": "2/14 (14.3%)"
                },
                "Annotation": {
                    "data": "1. Switch to IFX.\n2. Continue ETN.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 2.15 (0.47 to 9.85)",
                    "Absolute Effect (95% CI)": "164 more per 1,000 (from 76 fewer to 1,000 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "cbb72349",
        "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their first TNF Inhibitor who are not at target",
        "intervention": "Switch to a 2nd TNF Inhibitor",
        "comparator": "Continue same management",
        "outcome": "Disease activity (follow up: 4 months; assessed with: DAS28-ESR)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "ca0be03a"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to a 2nd TNFi": "13",
                    "Continue 1st TNFi": "14"
                },
                "Annotation": {
                    "data": "1. Switch to IFX.\n2. Continue ETN.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 1.2 lower (2.37 lower to 0.03 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "58ff0876",
        "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their first TNF Inhibitor who are not at target",
        "intervention": "Switch to a 2nd TNF Inhibitor",
        "comparator": "Continue same management",
        "outcome": "Remission (follow up: 4 months; assessed with: DAS28-ESR <2.6)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "ca0be03a"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size, very low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to a 2nd TNFi": "8/13 (61.5%)",
                    "Continue 1st TNFi": "2/14 (14.3%)"
                },
                "Annotation": {
                    "data": "1. Switch to IFX.\n2. Continue ETN.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 4.31 (1.11 to 16.67)",
                    "Absolute Effect (95% CI)": "473 more per 1,000 (from 16 more to 1,000 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "fff04d15",
        "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their first TNF Inhibitor who are not at target",
        "intervention": "Switch to a 2nd TNF Inhibitor",
        "comparator": "Continue same management",
        "outcome": "Radiographic progression (follow up: 4 months; assessed with: Sharp/ van der Heijde)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "ca0be03a"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of blinding of patients and personnel and lack of allocation concealment. Outcome assessors for radiographic outcomes were blinded."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to a 2nd TNFi": "12",
                    "Continue 1st TNFi": "12"
                },
                "Annotation": {
                    "data": "1. Switch to IFX.\n2. Continue ETN.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.6 higher (1.78 lower to 2.98 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "533c4bd1",
        "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their first TNF Inhibitor who are not at target",
        "intervention": "Switch to a 2nd TNF Inhibitor",
        "comparator": "Continue same management",
        "outcome": "Serious adverse events (follow up: 4 months)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "ca0be03a"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to a 2nd TNFi": "0/13 (0.0%)",
                    "Continue 1st TNFi": "2/14 (14.3%)"
                },
                "Annotation": {
                    "data": "1. Switch to IFX.\n2. Continue ETN.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.21 (0.01 to 4.08)",
                    "Absolute Effect (95% CI)": "113 fewer per 1,000 (from 141 fewer to 440 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "69adfd2a",
        "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their first TNF Inhibitor who are not at target",
        "intervention": "Switch to a 2nd TNF Inhibitor",
        "comparator": "Continue same management",
        "outcome": "Serious adverse events (from SR of harms)",
        "related_paper_list": [
            "a1e03f7a",
            "21011e18"
        ],
        "assessment_results": {
            "GRADE": {
                "result_interpretation": "The Systematic Review RefID=5595, 2011 comparing Infliximab vs Etanercept among RA and AS, Psoriasis, PsA, IBD, Cancer showed that for Serious adverse events, the result was OR=0.93 (0.60 to 1.42). The Systematic Review RefID=1403, 2017 comparing Infliximab vs Etanercept among RA showed that for Serious adverse events, the result was RR=4.90 (0.23 to 104) [Direct Evidence, Low certainty].",
                "Study design": "Systematic Review"
            }
        }
    },
    {
        "outcome_uid": "860632b4",
        "clinical_question": "Should patients with RA on their first TNF Inhibitor who are NOT at target, switch to a 2nd TNF Inhibitor or switch to a boDMARD targeting a different molecule or to a tsDMARD?",
        "population": "Patients with RA on their first TNF Inhibitor who are not at target",
        "intervention": "Switch to a 2nd TNF Inhibitor",
        "comparator": "Continue same management",
        "outcome": "Withdrawal due to adverse events (follow up: 4 months)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "ca0be03a"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to serious risk of bias. Lack of blinding (except for radiographic outcomes) and lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size, very low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "Switch to a 2nd TNFi": "2/13 (15.4%)",
                    "Continue 1st TNFi": "1/14 (7.1%)"
                },
                "Annotation": {
                    "data": "1. Switch to IFX.\n2. Continue ETN.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 2.15 (0.22 to 21.03)",
                    "Absolute Effect (95% CI)": "82 more per 1,000 (from 56 fewer to 1,000 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    }
]